Bremelanotide vs Melanotan II: Head-to-Head Comparison
Bremelanotide (PT-141/Vyleesi) is FDA-approved for hypoactive sexual desire disorder in premenopausal women. Melanotan II is an unregulated research peptide that affects sexual function, tanning, and appetite through broad melanocortin receptor activation. Bremelanotide was derived from Melanotan II but is more selective.
Side-by-Side Comparison
| Dimension | Bremelanotide | Melanotan II |
|---|---|---|
| Evidence Level | Phase III trials, FDA-approved | Limited clinical data; mostly anecdotal |
| FDA Status | FDA-approved (Vyleesi) for HSDD | Not approved; banned in several countries |
| Mechanism | MC4R agonist (selective melanocortin) | Non-selective MC1R/MC3R/MC4R/MC5R agonist |
| Side Effects | Nausea, flushing, headache; transient BP increase | Nausea, facial flushing, uncontrolled tanning, mole darkening, potential melanoma concern |
| Primary Use | Female sexual desire (HSDD) | Tanning and sexual function (both sexes) |
| Route of Administration | Subcutaneous auto-injector (on-demand) | Subcutaneous injection or nasal spray |
| Safety Profile | Well-characterized; FDA-reviewed safety data | Poorly characterized; melanoma risk concerns |
Peptide Overviews
Bremelanotide (PT-141)
AFDA ApprovedBremelanotide is a cyclic heptapeptide melanocortin receptor agonist approved by the FDA as Vyleesi for treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.
Melanotan II
CPreclinicalMelanotan II is a synthetic cyclic peptide analog of alpha-melanocyte stimulating hormone (alpha-MSH). Originally developed for skin tanning, it also has sexual arousal effects but significant safety concerns.
Bremelanotide vs Melanotan II: FAQ
Stay Informed on Peptide Research
Get weekly comparison updates, new study alerts, and regulatory changes.
No spam. Unsubscribe anytime.
Medical Disclaimer
This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.
Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.
No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.